xmab942
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2024 (NCT06619990)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFSF15 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06619990 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2024 | Galena Biopharma, Inc., Linear Clinical Research, Xencor |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galena Biopharma, Inc. | For profit | 1 | 1 | 1 | 2024 |
| Linear Clinical Research | For profit | 1 | 0 | 1 | 2024 |
| Xencor | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1